Kazia Therapeutics Limited. income statement KZIA

Annual Quarterly

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2023
Jun 30, 2023
FY 2022
Jun 30, 2022
FY 2021
Jun 30, 2021
FY 2020
Jun 30, 2020
FY 2019
Jun 30, 2019
FY 2018
Jun 30, 2018
Weighted average shares, basic
184
+39.1%
132
+12.6%
118
+61.1%
73
+27.0%
58
+18.9%
48
Weighted average shares, diluted
184
+39.1%
132
+12.6%
118
+61.1%
73
+27.0%
58
+18.9%
48
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
KZIA (Nasdaq)
Fiscal year ends
June 30
Incorporated in
Australia
Headquarters
Sydney Nsw
SEC filer status
Non-accelerated filer
SEC CIK
1075880
Former names
NOVOGEN LTD (until Nov 17, 2017)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.